查找临床试验
已按「多发性骨髓瘤」检索，对应国际通用词 multiple myeloma
共找到 12 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 10:14，每 5 分钟自动同步正在招募II 期NCT06762769
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
United Kingdom
年龄 18 Years – 不限
University College, London
正在招募III 期NCT03562169
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
United Kingdom
年龄 18 Years – 不限
University of Leeds
正在招募II 期NCT05847569
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
United States
年龄 18 Years – 不限
Mayo Clinic
正在招募I 期 / II 期NCT05850234
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
United States
年龄 18 Years – 不限
AstraZeneca
正在招募I 期 / II 期NCT05828511
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
United States、France、Spain
年龄 18 Years – 不限
Regeneron Pharmaceuticals
正在招募III 期NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
United States
年龄 18 Years – 不限
Grifols Biologicals, LLC
正在招募I 期NCT07558915
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Australia
年龄 18 Years – 不限
Genentech, Inc.
正在招募II 期NCT05091372
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
正在招募I 期中国有中心NCT07409246
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
United States、China、Israel、Japan
年龄 18 Years – 不限
AbbVie
正在招募不适用NCT06145581
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
United States
年龄 65 Years – 不限
Mayo Clinic
正在招募不适用NCT06874530
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
Italy
年龄 18 Years – 不限
IRCCS Azienda Ospedaliero-Universitaria di Bologna
正在招募II 期NCT06822972
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
United States
年龄 18 Years – 不限
Duke University